Recent advances in cytotoxins and immunotoxins are accelerating our understanding of cancer and leading to more effective therapeutic treatments. Although a large number of articles have been published on these cytotoxins and immunotoxins, this important information has yet to be compiled into one comprehensive resource.
For the first time, Cytotoxins and Immunotoxins for Cancer Therapy: Clinical Applications presents state-of-the-art information on various cytotoxins and immunotoxins in a single, highly anticipated publication. The editors bring together leading researchers to summarize their work and discuss clinical trial data concerning some of the most widely studied tumors. The book describes Pseudomonas exotoxin (PE)-based immunotoxins and presents the latest results from clinical trials for the treatment of recurrent glioblastoma and other human cancers. It reviews the role of ricin-based immunotoxins for the treatment of lymphoma, explores several DT-based immunotoxins, and details the preclinical and clinical development of the first FDA-approved cytotoxin.
With a focus on clinical developmental approaches to the use of cytotoxins and immunotoxins, this book discusses exciting possibilities for cancer therapy. It is a valuable resource for scientists, researchers, and clinicians involved in the development of new treatments that can help keep cancer under control, and may ultimately lead to a cure.
"With a focus on clinical developmental approaches to the use of cytotoxins and immunotoxins, this book discusses exciting possibilities for cancer research. It is a valuable resource for scientists, researchers, and clinicians involved in the development of new treatments that can help keep cancer under control, and may ultimately lead to a cure."
– In Anticancer Research, September/ October 2008, Vol. 27, No. 5A
Preface: An Overview of Immunotoxins and Cytotoxins in Clinical Trials
PART 1. PSEUDOMONAS EXOTOXIN (PE)-BASED IMMUNOTOXINS/CYTOTOXINS
Targeting of Pseudomonas Exotoxin-based Immunotoxins to Hematologic Malignancies, Robert J. Kreitman
Interleukin-4-targeted Cytotoxin for Recurrent Glioblastoma Therapy, Koji Kawakami, Mariko Kawakami, Robert J. Kreitman, and Raj K. Puri
Interleukin-13 Receptors and Development of IL-13-Pseudomonas Exotoxin for Human Cancer Therapy, Bharat H. Joshi, Syed R. Husain, Pamela Leland, and Raj K. Puri
PART 2. RICIN-BASED IMMUNOTOXINS/CYTOTOXINS
Ricin Immunotoxins in Lymphomas, Ronald Schnell and Andreas Engert
PART 3. DIPHTHERIA TOXIN (DT)-BASED IMMUNOTOXINS/CYTOTOXINS
Diphtheria-based Immunotoxins: Targeting Overexpressed Interleukin-13 Receptor and Urokinase-type Plasminogen Activator Receptor on Glioblastoma Multiforme, Edward Rustamzadeh, Walter A. Hall, Deborah Todhunter, and Daniel Vallera
DAB389IL-2 (Ontak): Development and Therapeutic Applications, Paul J. Shaughnessy, and Charles F. LeMaistre
Transferrin Diphtheria Toxin for Brain Tumor Therapy, Simon Long and Patrick Rossi
GM-CSF Receptor Targeted Therapy of Human Leukemia, Arthur E. Frankel, Philip D. Hall, Dongsun Cao, Tie Fu Liu, Marlena Moors, Kimberley A. Cohen, Andrew M. Thorburn, and Robert J. Kreitman
VEGF-diphtheria toxin for Targeting of Tumor Blood Vessels, Indira V. Subramanian, and Sundaram Ramakrishnan
PART 4. MISCELLANEOUS
cBR-96-doxorubicin (SGN-15) for Metastatic Breast Cancer Therapy, Lisle Nabell, Clay B. Siegall, and Mansoor N. Saleh
Anti-CD33 Calicheamicin Immunoconjugate Therapy of Acute Myeloid Leukemia, Charalambos Andreadis, Selina M. Luger Selina, and Edward A. Stadtmauer